Parkinson’s disease dementia
Parkinson’s disease dementia is dementia that appears in the setting of established Parkinson’s disease. Rivastigmine has an FDA indication for this use and is a symptom treatment, not disease-modifying.
Overview
When dementia develops after established Parkinson’s disease, clinicians may diagnose Parkinson’s disease dementia. Overlap with dementia with Lewy bodies is biological. Rivastigmine is labeled in the US for mild-to-moderate dementia associated with Parkinson’s disease. Movement, sleep, hallucinations, and blood-pressure changes still shape the care plan.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Rivastigmine may be considered. Coordinate with the movement-disorder plan and avoid harmful antipsychotics where possible.
Subtypes & biomarkers
topDated changes read from the records linked to this diagnosis: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 2 changes by month →What is in development for Parkinson’s disease dementia, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this diagnosis, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this diagnosis yet.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Who & centres
topOrganisations and centres
This atlas lists sourced companies, institutions, and public figures — not a “see this doctor” directory. Start from Who or the institutions index, and ask the person’s clinical team about a memory clinic referral.
No institutions are linked to this diagnosis yet.
For urgent help and helplines, see resources.
Questions to ask
topQuestions to ask your clinician about Parkinson’s disease dementia
Newly diagnosed
- What is my exact diagnosis, and which assessments established it?Why: Care plans follow from an accurate diagnosis and how it was confirmed.
- Is genetic testing recommended for me or my family, and what counselling comes with it?Why: Inherited variants can change counselling and, rarely, care; they matter for relatives too.
Cognitive symptoms
- For my situation (cognitive symptoms), which of the standard options do you recommend and why?Why: Guideline options include: Rivastigmine may be considered. Coordinate with the movement-disorder plan and avoid harmful antipsychotics where possible.
- Am I a candidate for Rivastigmine, and what side effects should I expect?Why: Knowing expected effects helps you plan work, family, and supportive care.
Any stage
- Would a second opinion at a memory clinic or specialist centre change anything, and can you help arrange it?Why: Complex or high-stakes decisions benefit from a centre that sees many similar patients.
- What supportive care (symptom control, carer support, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps people stay on a plan that fits them.
Start from the care guide for household next steps, and use resources for helplines.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this diagnosis's products.
targets
2drugs
1Latest papers
topQuery for this diagnosis: (TITLE:"Parkinson’s disease dementia" OR ABSTRACT:"Parkinson’s disease dementia") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Parkinson’s disease dementia, not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyCholinesterase inhibitors
Shares Rivastigmine, Dementia with Lewy bodies and the tag dementia-atlas.
- BottleneckWrong-subtype treatment
Shares Dementia with Lewy bodies, Dementia (umbrella) and the tag dementia-atlas.
- TreatmentDonepezil
Shares Acetylcholinesterase and the tag dementia-atlas.
- TreatmentGalantamine
Shares Acetylcholinesterase and the tag dementia-atlas.
- TermMild cognitive impairment
Shares Dementia (umbrella) and the tag dementia-atlas.
- TermMixed dementia
Shares Dementia (umbrella) and the tag dementia-atlas.
- TechnologyDementia care navigation
Shares Dementia (umbrella) and the tag dementia-atlas.
- BottleneckLate and uneven diagnosis
Shares Dementia (umbrella) and the tag dementia-atlas.